Evidence map›Paper›PMID 35426179›Full record

SynthesisJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2022

Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.

Tatiane Vilaca, Nalini Velmurugan, Christopher Smith, Bo Abrahamsen, Richard Eastell

Open access · hybridAbstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Review
  6. Iron overload induced by ferric derisomaltose and ferric carboxymaltose both increase FGF-23 levels and lead to osteomalacia and bone loss in normal mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Tatiane VilacaDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.ORCID 0000-0002-9227-6076
Nalini VelmuruganDepartment of Medicine, Holbaek Hospital, Holbaek, Denmark.
Christopher SmithOpen Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Bo AbrahamsenDepartment of Medicine, Holbaek Hospital, Holbaek, Denmark.ORCID 0000-0002-2730-6080
Richard EastellDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.ORCID 0000-0002-0323-3366
University of Sheffield · GBUniversity of Southern Denmark · DKHolbæk Sygehus · DK

Funding

Medical Research Council MR/P020941/1Pharmacosmos
6 · The paper itself

Abstract

Randomized control trials (RCTs) have shown that certain intravenous iron preparations can induce high levels of fibroblast growth factor 23 (FGF-23) and persistent hypophosphatemia. Repeated iron infusions may lead to prolonged hypophosphatemia and osteomalacia events not captured by RCTs. Several previous case reports have described skeletal adverse effects after repeated iron infusions. To characterize these effects, we conducted a systematic review of case reports. MEDLINE, Embase, Web of Science, and Cochrane databases were searched in March 2021. We selected case reports of patients ≥16 years old. Study quality was assessed using the tool from Murad and colleagues. We report the results in a narrative summary. We identified 28 case reports, reporting 30 cases. Ages ranged from 28 to 80 years (median 50 years). Most patients (n = 18) received ferric carboxymaltose (FCM), whereas 8 received saccharated ferric oxide (SFO) and 3 received iron polymaltose (IPM). All but 2 cases had more than five infusions (range 2 to 198, median 17). The lowest phosphate levels ranged from 0.16 to 0.77 mmol/L (median 0.36 mmol/L). Intact FGF-23 (iFGF-23) was high when measured. Serum 25OH vitamin D was low in 10 of 21 cases measured and 1,25(OH)

Indexed as

Anemia, Iron-DeficiencyFamilial Hypophosphatemic RicketsHypophosphatemiaOsteomalaciaAdolescentAdultAgedAged, 80 and overAlkaline PhosphataseFerric CompoundsFibroblast Growth FactorsHumansIronMiddle AgedMineralsPhosphatesAlkaline PhosphataseFerric CompoundsFibroblast Growth FactorsIronMineralsPhosphatesVitamin DFGF-23FRACTURESHYPOPHOSPHATEMIAIRON INFUSIONOSTEOMALACIA

Identifiers

PMID35426179
PMCPMC9322686
OpenAlexW4223958261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.